THERAPY DOSSIER · th-458c53c2a114

Zonisamide-loaded monomethyl poly(ethylene glycol)-poly(l-lactide)-poly(trimethylene carbonate) nanomicelles (approximately 50 nm)

Drug · Sodium channel alpha subunit blocker (BLOCKER, direct interaction)

No trauma translation Suggest a correction

This record is classified as “NO TRAUMA TRANSLATION”. Read the indication and notes below for the specific context.

Evidence & regulatory context

Mechanism: Sodium channel alpha subunit blocker (BLOCKER, direct interaction)
Target: CHEMBL2331043
Injury models: Spinal cord injury
Reported indication: Adjunctive therapy for partial seizures / epilepsy (Zonegran; approved 2000)
First approval: 2000
Development stage: Approved antiepileptic; hearing-loss neuroprotection trial terminated
ChEMBL record: CHEMBL750 ↗
ChEMBL max phase: 4 / 4 (development scale, not regulatory approval)
Synonyms: Zonegran; Excegran; AD-810; CI-912; PD-110843; Zonisade
Note: Not recorded

Clinical trials 6

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT03376139 ↗Injury indicationPHASE2withdrawn

Zonisamide as a new treatment for PTSD and co-occurring alcohol use disorder

Post Traumatic Stress Disorder · Alcohol Use Disorder

Enrolment: 0 · Results not recorded

NCT01630057 ↗PHASE4completed

Adjunctive zonisamide vs replacement with zonisamide of last added antiepileptic drug

Partial Seizures

Enrolment: 200 · Results not recorded

NCT00056576 ↗PHASE3completed

Dose-response, safety and efficacy of Zonegran (zonisamide) as monotherapy in newly diagnosed epilepsy

Epilepsy, Complex Partial

Enrolment: 165 · Results not recorded

NCT00566254 ↗PHASE3completed

Adjunctive zonisamide in paediatric partial onset seizures

Epilepsy; Paediatric Partial Onset Seizures

Enrolment: 207 · Results not recorded

NCT04768569 ↗PHASE2terminated

Pharmaceutical interventions for noise-induced hearing loss - acute exposure treatment (zonisamide)

Hearing Loss, Noise-Induced

Enrolment: 24 · Results not recorded

NCT00275834 ↗NAcompleted

Zonisamide for weight reduction in obese adults

Obesity

Enrolment: 225 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28408816 ↗2017Reported benefit

Zonisamide-loaded triblock copolymer nanomicelles as a novel drug delivery system for the treatment of acute spinal cord injury.

RatSpinal cord injuryHemisection / partialSprague-Dawley (HFK Bioscience)Malen = Four main experimental groups, 7 rats per groupIntravenous10 mg/kg zonisamide, redissolved in normal saline at 1 mg/mL6 hours and 4 days after surgery

Model: Right-sided hemisection of the T10 spinal cord with a sharp blade after removal of the dorsal vertebra, under chloral hydrate anaesthesia

Zonisamide-loaded micelles reduced the atrophied cord area, improved Basso Beattie Bresnahan scores at 4 weeks and increased neuron and axon density relative to free drug, blank micelles and saline.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…